ISSN: 1859 - 2872
Applying transarterial chemoembolization (Tace) for treatment of hepatocellular carcinoma at Thai Nguyen Oncology Center
Main Article Content
Keywords
Abstract
Objective: To describe the clinical features and the result of transarterial chemoembolization (TACE) in primary hepato - cellular carcinoma at Thainguyen national hospital from August 2016 to August 2020. Subject and method: 58 patients who diagnosed with hepato-cellular carcinoma (HCC) were treated by TACE at Thainguyen national hospital from August 2016 to August 2020. Result: The average age of patients was 56.4 ± 11.9 years old. The location of tumors was mainly in the right lobe of liver, accounting for 82.8%. The average size of the tumors was 7.5 ± 3.2cm. The group of patients with tumor’s size from 5cm to 10cm accounted for 44.8%. After 1 month, 26.3% of patients still had right hypochondrium pain compared with 58.6% before embolization. The average size of the tumors before the embolization was 71.2 ± 27.5mm, and after 1 month, The average size was 67.9 ± 25.9mm. The mean overall survival (OS) was 20.8 ± 1.9 months (95% CI: 17.2 - 24.5). The OS after 6 months, 12 months, 24 months were 91.2%, 76.3%, 30.5% respectively. Patients with tumor’s size < 5cm had mean survival time of 26.1 ± 3.2 months, while the group of patients with tumors > 10cm had a shortest mean survival time (p<0.001). The mean survival time of the group of patients who had with 2 or more TACE times was 31.3 ± 4.1 months, which was statistically significantly higher than the group of patients with only one time of TACE (16.9 ± 1.5 months) (p=0.002). Conclusion: TACE was an effective treatment for HCC patients. The outcome was better in the group of patients with tumor’s size under 5 cm. Additional TACE also resulted in higher treatment efficacy for HCC patients.
Article Details
References
2. Gish RG, Bui TD, Nguyen CT et al (2012) Liver disease in Viet Nam: Screening, surveillance, management and education: A 5-year plan and call to action. J Gastroenterol Hepatol 27(2): 238-247.
3. Raoul JL, Forner A, Bolondi L Cheung et al (2019) Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 72: 28-36.
4. Nguyễn Quang Thành (2014) Đánh giá kết quả tắc mạch gan bằng hóa dầu điều trị ung thư biểu mô tế bào gan tại Bệnh viện Việt Tiệp Hải Phòng. Chuyên ngành Ung thư.
5. Barman, Pranab M, Sharma et al (2014) Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Digestive diseases and sciences 59(11): 2821-2825.
6. Nguyễn Quốc Hùng (2013) Ứng dụng phương pháp tắc mạch can thiệp trong điều trị ung thư biểu mô tế bào gan nguyên phát. Tạp chí Điện quang Việt Nam 12: 553-559.
7. Ren, Yanqiao, Cao et al (2019) Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: Results of a single-center retrospective case control study. BMC cancer. 19(1): 983-983.
8. Liu YS, Lin CY, Chuang MT et al (2018) Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 18(1): 124.
9. Baek, Min Young, Yoo, Jeong-Ju, Jeong, Soung Won et al (2019) Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. The Korean journal of internal medicine 34(6): 1223-1232.
10. Terzi E, Piscaglia F, Forlani et al (2014) TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 14: 601.
11. Zhu, Kai, Dai et al (2013) Biomarkers for hepatocellular carcinoma: Progression in early diagnosis, prognosis, and personalized therapy. Biomarker Research 1(1): 10.
Article Sidebar
